Information Hub

Clinical News

2019-06-04

A novel Her2-targeted antibody-conjugate showed activity in trastuzumab emtansine-pretreated patients with Her2-positive breast cancer

A dose expansion phase I clinical trial data revealed the efficacy of trastuzumab deruxtecan (DS-8201a) in trastuzumab emtansine-pretreated patients with Her2-positive breast cancer

Source:

Lancet Oncol

2019-06-04

Lorlatinib showed the anti-tumor efficacy in ALK inhibitor-pretreated NSCLC patients with ALK mutation

A phase II clinical trial data revealed the efficacy of lorlatinib in ALK mutation-positive NSCLC patients who have failed prior ALK inhibitor. Furthermore, the ALK mutations identified by tissue genotype can predict the potential clinical benefits of lor

Source:

J Clin Oncol. 2019

2019-06-04

Pertuzumab Plus Trastuzumab Shows Potential Treatment-Refractory HER2-Positive Metastatic Colorectal Cancer

In an ongoing, phase 2a, multiple basket study (MyPathway), combination of pertuzumab and trastuzumab showed encouraging activity in patients with treatment-refractory HER2+ metastatic CRC, especially for those with KRAS wild-type tumors.

Source:

Lancet Oncol. 2019

2019-05-02

LOXO-195 Shows Good Activity In Patients Who Have Failed After Prior Anti-TRK Therapy

In a phase 1 study, LOXO-195 showed promising results in multiple cancer types after failure of initial anti-TRK therapy

Source:

2019 AACR

2019-05-02

Maintenance Rucaparib Shows Encouraging Disease Control In Pancreatic Cancer Patients With BRCA1, BRCA2 or PALB2 Mutation

Rucaparib maintenance following platinum-based chemotherapy shows encouraging disease control in BRCA1/2 or PALB2-mutant pancreatic cancer

Source:

2019 AACR

2019-05-02

MET Amplification Is A Potential Biomarker For NSCLC Patients Resistant To 1st And 2nd EGFR Inhibitor Treatment

A phase Ib clinical trial (TATTON) data revealed the efficacy of osimertinib plus savolitinib in MET-amplified NSCLC patients after progression on EGFR inhibitor treatment.

Source:

2019 AACR

2019-03-28

Neratinib shows clinical benefit in HER2-mutant cervical cancer patients

According to the results from the phase 2 SUMMIT basket trial, neratinib demonstrated clinical efficacy in patients with metastatic HER2-mutant cervical cancer.

Source:

2019 SGO Annual Meeting

2019-03-28

Avapritinib demonstrates clinical activity in patients with advanced gastrointestinal stromal tumors with KIT and PDGFRA mutations

According to the results from the phase I NAVIGATOR trial presented at the 2018 CTOS Annual Meeting, avapritinib showed substantial clinical benefit across all lines of therapy for GIST patients.

Source:

2018 CTOS Annual Meeting

2019-03-28

Crizotinib demonstrates clinical activity among patients with inflammatory myofibroblastic tumor (IMFT)

According to a result from a phase 2 study, crizotinib showed positive results in patients with advanced, inoperable inflammatory myofibroblastic tumors.

Source:

2018 CTOS Annual Meeting

2019-03-05

Combination of Dabrafenib and Trametinib Shows Clinical Benefit in Patients with BRAF-Mutant Biliary Tract Cancer

In the phase 2 basket ROAR study, combination of dabrafenib and trametinib demonstrated clinical benefit in patients with BRAF-mutant biliary tract cancer.

Source:

J Clin Oncol 37, 2019